<DOC>
	<DOCNO>NCT03097133</DOCNO>
	<brief_summary>The purpose study evaluate efficacy intranasal esketamine 84 milligram ( mg ) compare intranasal placebo addition comprehensive standard care reduce symptom Major Depressive Disorder ( MDD ) , include suicidal ideation , participant assess imminent risk suicide , measure change baseline Montgomery-Asberg Depression Rating Scale ( MADRS ) total score 24 hour post first dose .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety Intranasal Esketamine Addition Comprehensive Standard Care Rapid Reduction Symptoms Major Depressive Disorder , Including Suicidal Ideation , Adult Participants Assessed Imminent Risk Suicide</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Suicide</mesh_term>
	<mesh_term>Suicidal Ideation</mesh_term>
	<mesh_term>Antidepressive Agents</mesh_term>
	<criteria>Participant must meet Diagnostic Statistical Manual Mental Disorders ( 5th edition ) ( DSM5 ) diagnostic criterion major depressive disorder ( MDD ) , without psychotic feature , base upon clinical assessment confirm Mini International Psychiatric Interview ( MINI ) Participants must current suicidal ideation intent , confirm `` Yes '' response Question B3 [ Think ( even momentarily ) harm hurt injuring : least intent awareness might die result ; think suicide ( ie , kill ) ? ] AND Question B10 [ Intend act thought kill ? ] obtain MINI In physician 's opinion , acute psychiatric hospitalization clinically warrant due participant 's imminent risk suicide Participant Montgomery Asberg Depression Rating Scale ( MADRS ) total score great ( &gt; ) 28 predose Day 1 As part standard care treatment , participant agrees hospitalize voluntarily recommended period 5 day randomization ( may shorter longer clinically warranted investigator 's opinion ) take prescribed noninvestigational antidepressant therapy ( y ) least duration doubleblind treatment phase ( Day 25 ) Participant current DSM5 diagnosis bipolar ( related disorder ) , antisocial personality disorder , obsessive compulsive disorder Participant currently meet DSM5 criterion borderline personality disorder . Note : Participant meeting full DSM5 criterion borderline personality disorder exhibit recurrent suicidal gesture , threat , selfmutilating behavior also exclude Participant current clinical diagnosis autism , dementia , intellectual disability Participant current prior DSM5 diagnosis psychotic disorder , MDD psychotic feature Participant history moderate severe substance alcohol use disorder , accord DSM5 criterion , except nicotine caffeine , within 6 month Screening Participant history current sign symptom liver renal insufficiency clinically significant cardiac , vascular , pulmonary , gastrointestinal , endocrine , neurologic ( include current past history seizure except uncomplicated childhood febrile seizure sequelae ) , hematologic , rheumatologic , metabolic disease Participant know allergy , hypersensitivity , intolerance contraindication esketamine ketamine excipients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>